Related Experiment Video
Updated: Mar 13, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis
Puneeta Tandon1, K Rajender Reddy2, Jacqueline G O'Leary3
1University of Alberta, Edmonton, AB, Canada.
Insights
A new Karnofsky Performance Status (KPS) score helps identify cirrhosis patients at high risk of 3-month mortality after hospital discharge, guiding early interventions and palliative care strategies.
Area of Science:
- Hepatology
- Clinical Prognostics
- Patient Outcomes
Background:
- Identifying cirrhosis patients at high risk for 3-month postdischarge mortality is crucial for tailoring care plans.
- The Karnofsky Performance Status (KPS) is a potential tool for risk stratification in these patients.
Purpose of the Study:
- To develop and validate an accessible prognostic model for predicting 3-month mortality in cirrhosis patients using KPS.
- To compare the predictive accuracy of a KPS-based model against existing models like the Model for End-Stage Liver Disease (MELD).
Main Methods:
- Prospective enrollment of 954 cirrhosis patients across 16 hepatology centers.
- KPS assessment at one week postdischarge, categorized into low, intermediate, and high performance groups.
- Development of a prognostic model incorporating KPS, age, and MELD score to predict 3-month mortality.
Main Results:
- Mortality rates were significantly higher in the low KPS group (23%) compared to intermediate (11%) and high (5%) groups.
- Low KPS was associated with older age, dialysis, hepatic encephalopathy, longer hospital stay, and higher MELD scores.
- The KPS-based model demonstrated superior discrimination (AUC=0.74) compared to MELD alone (AUC=0.62) or MELD and age (AUC=0.67).
Conclusions:
- A novel KPS-based prognostic score effectively identifies cirrhosis patients at risk for 3-month postdischarge mortality.
- This KPS score can guide the implementation of early interventions, including palliative care, for high-risk patients.
Abstract:
Identification of patients with cirrhosis at risk for death within 3 months of discharge from the hospital is essential to individualize postdischarge plans. The objective of the study was to identify an easy-to-use prognostic model based on the Karnofsky Performance Status (KPS). The North American Consortium for the Study of End-Stage Liver Disease consists of 16 tertiary-care hepatology centers that prospectively enroll nonelectively admitted cirrhosis patients. Patients enrolled had KPS assessed 1 week postdischarge. KPS was categorized into low (score 10-40), intermediate (50-70), and high (80-100). Of 954 middle-aged patients (57 ± 10 years, 63% men) with a median Model for End-Stage Liver Disease (MELD) score of 17 (interquartile range 13-21), the mortality rates for the low, intermediate, and high performance status groups were 23% (36/159), 11% (55/489), and 5% (15/306), respectively. Low, intermediate, and high performance status was seen in 17%, 51%, and 32% of the cohort, respectively. Low performance status was associated with older age, dialysis, hepatic encephalopathy, longer length of stay, and higher white blood cell count or MELD score at discharge. A model was derived using the three independent predictors of 3-month mortality: KPS, age, and MELD score. This score had better discrimination (area under the receiver operating characteristic curve = 0.74) than a model using MELD (area under the receiver operating characteristic curve = 0.62) or MELD and age (area under the receiver operating characteristic curve = 0.67) to predict 3-month mortality.
Conclusions:
Cirrhosis patients at risk for 3-month postdischarge mortality can be identified using a novel KPS-based score; this score may be adopted in practice to guide postdischarge early interventions, including the integrated provision of active and palliative management strategies. (Hepatology 2017;65:217-224).
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug